In prostate cancer [32], SNHG3 might serve as a diagnostic biomarker, as its expression levels can successfully differentiate prostate cancer tissues from normal prostate tissues based on the TCGA-PRAD database (area under the curve (AUC) = 0.917, 95% confidence interval [CI]: 0.867–0.966). This evidence concerns the gene SNHG3 and prostate cancer.